2018
DOI: 10.3390/molecules23030630
|View full text |Cite
|
Sign up to set email alerts
|

In Vitro ADME Properties of Two Novel Antimicrobial Peptoid-Based Compounds as Potential Agents against Canine Pyoderma

Abstract: Antimicrobial peptides (AMPs) hold promise as the next generation of antimicrobial agents, but often suffer from rapid degradation in vivo. Modifying AMPs with non-proteinogenic residues such as peptoids (oligomers of N-alkylglycines) provides the potential to improve stability. We have identified two novel peptoid-based compounds, B1 and D2, which are effective against the canine skin pathogen Staphylococcus pseudintermedius, the main cause of antibiotic use in companion animals. We report on their potential … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
10
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(10 citation statements)
references
References 61 publications
0
10
0
Order By: Relevance
“…However, the vast literature and clinical trials on AMPs did not result in systemic therapy and treatments [ 151 ]. AMPs are active selectively at micromolar concentrations and prone to have their chemical synthesis optimized despite their short half-life in vivo and high scaling-up costs of production making difficult the commercial uses [ 25 , 152 ]. De novo design of AMPs following a peptide-mimetic approach [ 153 ] yields peptoids [ 154 , 155 , 156 ], peptide–peptoid hybrids [ 157 ] and α-peptide/β-peptoids [ 158 ] with increased in vivo stability and resistance against proteolytic degradation.…”
Section: Bsa With Peptidesmentioning
confidence: 99%
See 2 more Smart Citations
“…However, the vast literature and clinical trials on AMPs did not result in systemic therapy and treatments [ 151 ]. AMPs are active selectively at micromolar concentrations and prone to have their chemical synthesis optimized despite their short half-life in vivo and high scaling-up costs of production making difficult the commercial uses [ 25 , 152 ]. De novo design of AMPs following a peptide-mimetic approach [ 153 ] yields peptoids [ 154 , 155 , 156 ], peptide–peptoid hybrids [ 157 ] and α-peptide/β-peptoids [ 158 ] with increased in vivo stability and resistance against proteolytic degradation.…”
Section: Bsa With Peptidesmentioning
confidence: 99%
“…De novo design of AMPs following a peptide-mimetic approach [ 153 ] yields peptoids [ 154 , 155 , 156 ], peptide–peptoid hybrids [ 157 ] and α-peptide/β-peptoids [ 158 ] with increased in vivo stability and resistance against proteolytic degradation. Most studies have been performed with short peptoids up to four residues.For example, a recent study described a peptide-peptoid hybrid, B1, and a peptoid, D2, that were highly active against Staphylococcus pseudintermedius (MIC 2–4 µg/mL) and exhibited potential as topical treatment against canine pyoderma [ 152 ]. Figure 9 illustrates the chemical structure of these interesting peptidomimetic molecules obtained by copying AMPs regarding their hydrophobicity and cationic character which gather positively charged and hydrophobic moieties for optimal activity as reproduced from [ 152 ].…”
Section: Bsa With Peptidesmentioning
confidence: 99%
See 1 more Smart Citation
“…Thus, they act quickly and selectively against bacteria at micromolar concentrations [9]. AMPs, as the next generation of antibacterials, are the object of rapidly-growing research interest and may also be promising antimicrobials for the treatment of staphylococcal skin infections in dogs, particularly where antibiotic therapy may be limited because of multidrug resistance [10].…”
Section: Introductionmentioning
confidence: 99%
“…D2D is a full d-amino acid analog derived from a structure-activity relationship study of the peptoid D2. Furthermore D2, was selected in a previous study after screening from a combinatorial library of de novo designed compounds for their activity against S. pseudintermedius and toxicity in vitro against red blood cells [19].…”
Section: Introductionmentioning
confidence: 99%